Home/All Molecules/Sitagliptin

Sitagliptin Range

Comprehensive Sitagliptin portfolio for Franchise & Manufacturing.

Category
sitagliptin
Total Formulations
14
Available Forms
Tablets

Expand Your Business with Our Multiple Divisions


Browse Sitagliptin portfolio by Dosage Form


The Cafoli Advantage for PCD Franchise & Manufacturing

WHO-GMP Quality

Every Sitagliptin batch undergoes rigorous in-house and third-party testing, strictly adhering to WHO-GMP standards for efficacy and safety.

Quality Policy

Monopoly & Branding

Secure exclusive PCD franchise rights for your territory and benefit from our range of premium, marketing-driven product packaging.

Market Strategy

Sales Support

Enhance your sales with Cafoli’s complete kit of marketing materials, including visual aids, MR bags, catch covers, and product cards.

Marketing Tools

Sitagliptin PCD Pharma Franchise Company

Sitagliptin PCD Pharma Franchise Company

Cafoli Lifecare is a trusted Sitagliptin PCD pharma franchise company in India, offering 14 Sitagliptin formulations in tablet form, covering both plain strengths and widely prescribed fixed-dose combinations. All products are manufactured at WHO-GMP certified facilities with DCGI-approved compositions, giving franchise partners a strong anti-diabetic portfolio.

What is Sitagliptin?

Sitagliptin is an oral anti-diabetic drug of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It blocks the DPP-4 enzyme that normally degrades incretin hormones such as GLP-1 and GIP, so incretin levels rise, insulin release increases in a glucose-dependent manner and glucagon secretion falls. It is used to improve glycaemic control in adults with type 2 diabetes mellitus. Pharmacological details are available on PubChem.

Therapeutic Applications of Sitagliptin

Sitagliptin is indicated as an adjunct to diet and exercise in type 2 diabetes mellitus, used as monotherapy where metformin is not tolerated, and more commonly as add-on therapy with metformin, sulfonylureas or SGLT2 inhibitors. It is prescribed principally by diabetologists and endocrinologists, and in very large volumes by consulting physicians and general practitioners.

Why Sitagliptin is a High-Potential Molecule for Distributors

Sitagliptin's patent expiry in India reset its commercial profile: prices fell, generic competition opened up, and the molecule moved out of the specialist-only bracket into everyday second-line prescribing after metformin. Its clinical advantages drive that shift, since it is weight-neutral and carries a low intrinsic risk of hypoglycaemia, which makes physicians comfortable prescribing it to elderly patients and to those who cannot tolerate sulfonylureas. Diabetes is lifelong, so every conversion becomes a permanent monthly reorder, and the fixed-dose combination formats let a distributor hold several SKUs of the same molecule in one territory.

Why Choose Cafoli Lifecare

We offer real district monopoly rights, WHO-GMP certified manufacturing, DCGI-approved compositions and a complete promotional support package including visual aids, samples, prescription pads, MR bags and doctor gifts. More than 1000+ partners across India work with Cafoli Lifecare.

References

  1. PubChem – Sitagliptin compound record
  2. MedlinePlus – Sitagliptin drug information
  3. PubMed – clinical literature on Sitagliptin

Aceclofenac in Modern Clinical Practice

Our formulations of Sitagliptin find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to:


FAQ about Sitagliptin in PCD Franchise

Start Your Sitagliptin Franchise with Cafoli Lifecare

Ready to build your own Sitagliptin distribution business? Cafoli Lifecare offers monopoly-based PCD pharma franchise rights, WHO-GMP certified manufacturing and complete promotional support. Call 9518447302 or email info@cafoli.in to check district availability and receive our latest price list.

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions (FAQs)

Cafoli Lifecare lists 14 Sitagliptin tablet formulations, including single-molecule strengths and fixed-dose combinations commonly used in type 2 diabetes. The composition-wise list with packing and pricing is shared on enquiry.

Yes. Sitagliptin is offered on a district monopoly basis, so only one Cafoli franchise partner is appointed per territory. Availability is confirmed once your Drug License is verified.

Sitagliptin is prescribed by diabetologists and endocrinologists, and extensively by consulting physicians and general practitioners who manage type 2 diabetes in day-to-day practice.

Sitagliptin came off patent in India, which brought prices down sharply and moved it from a specialist drug to routine second-line therapy after metformin. It is weight-neutral and carries a low risk of hypoglycaemia, so physicians are comfortable using it long term, and diabetes therapy is lifelong. That combination of wide prescribing and permanent repeat demand is what makes it a core anti-diabetic line.

A valid Drug License and GST registration number are required to begin the appointment process with Cafoli Lifecare.